Stay updated on Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial
Sign up to get notified when there's something new on the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page.

Latest updates to the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 removed, indicating a minor metadata update to the page.SummaryDifference0.1%

- Check22 days agoChange DetectedAdded a new 'Moffitt Cancer Center Clinical Trials website' link and the sponsor organization name 'H. Lee Moffitt Cancer Center and Research Institute.' Introduced a new 'Helpful Links Provided by' section to house related links.SummaryDifference0.2%

- Check29 days agoChange DetectedDeleted the Study Protocol and Statistical Analysis Plan PDF along with several boilerplate/footer items from the study page.SummaryDifference20%

- Check36 days agoChange DetectedThe update appears to be a site-wide template revision (Revision: v3.4.2) with removal of certain footer sponsor links; these changes do not modify the trial details or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check43 days agoChange DetectedThe page revision updates from v3.4.0 to v3.4.1, with no substantive changes to study details, eligibility criteria, outcomes, or timelines.SummaryDifference0.1%

Stay in the know with updates to Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page.